Predictors of de-escalation of P2Y12 inhibitors to clopidogrel in patients with acute myocardial infarction treated with percutaneous coronary intervention
Key takeaway
This retrospective study, the first study to detail the reasons for P2Y12 inhibitor de-escalation revealed that:
- Patients with AMI treated with PCI were frequently de-escalated to clopidogrel prior to discharge following initial treatment with potent P2Y12 inhibitor
- De-escalation was performed because of clinical/non-clinical factors and reasons were poorly documented by the clinicians, representing an area for improvement
Why this matters
- In patients with ACS undergoing PCI, potent P2Y12 inhibitors ticagrelor and prasugrel have shown superior efficacy in reducing ischemic complications and stent thromboses vs clopidogrel, but with an increased bleeding risk.*
- Patients treated with more potent P2Y12 inhibitors are often deescalated to clopidogrel; however, the reasons were not well defined in the existing literature or registries.
This study assessed the incidence and predictors of in-hospital de-escalation from a potent P2Y12 inhibitor to clopidogrel in a cohort of patients with AMI PCI.
Study design
A retrospective study was conducted in two tertiary centers at USA using data obtained from the electronic health record and institutional NCDR CathPCI.
Patients included
Consecutive patients who received ticagrelor or prasugrel loading dose for AMI PCI with a drug eluting stent between Jan 2015 and Mar 2019 who survived to discharge.
Analyses
Patients de-escalated to clopidogrel were compared with those who remained on potent P2Y12 inhibitors through the time of discharge.
Data evaluated
- The risk of bleeding prediction for all patients were determined using the PRECISE-DAPT score.
- Manual chart review of all patients was performed to identify the documented reason(s) for P2Y12 de-escalation.
Key results
Of the 1,818 included patients in the overall cohort, 1,146 (63%) patients underwent P2Y12 inhibitor de-escalation. (age = 65.1 ± 13.1 years; men = 69%)
Patients characteristics
Patients on medications |
|
|
De-escalation group vs No De-escalation group | ||
Age | 65.1 years vs 63.7 years | |
Black Race | 6.0% vs 2.3% | |
Caucasian Race | 91% vs 94.6% | |
Diabetes Prevalence | 30.2% vs 37.2% | |
Private Insurance | 76.0% vs 83.2% | |
Bleeding Risk | Similar in both groups | |
PCI Complexity | Less complex PCI | |
Patient History† |
|
|
|
Factors Associated with De-escalation
Positive Association | |
Older Age |
|
Negative Association | |
Caucasian Race |
|
Prior MI |
|
Bifurcation Lesion Intervention |
|
Greater number of Stents |
|
|
Decision for De-escalation
|
Key limitations
- High number of patients de-escalated without a documented reason.
- Data on patient preferences were not collected.
- This study was not powered to analyze separately ticagrelor and prasugrel, and lesion subsets such as left main or chronic total occlusions.
* Evidence suggest that tailoring antiplatelet regimens based on patient’s bleeding and ischemic risk may improve outcomes than a universally applied strategy
† While prevalence of known coronary artery disease was high and they were at ischemic risk
Abbreviations
ACS, acute coronary syndrome; AMI, acute myocardial infarction; CI, confidence interval; MI, myocardial infarction; OR, odds ratio; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction.
Reference
- Williams MU, Lang WR, Wark T, Ovide G, Mitsuyama R, Kadiyala V, et al. Predictors of in-hospital de-escalation of P2Y12 inhibitors to clopidogrel in patients with acute myocardial infarction treated with percutaneous coronary intervention. Cardiovasc Revasc Med. 2022:S1553-8389(22)00055-0. doi: 10.1016/j.carrev.2022.01.029. Epub ahead of print. PMID: 35181265.
Interested to know more about our products?
Disclaimer: The images depicted here are fictitious and meant for illustrative purpose only. Any resemblance to any person, living or dead is purely coincidental.